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Complex traitincluding copy-number variation (CNV), constitutes a substantial fraction of total
genetic variability and the importance of structural genetic variants in modulating human disease is
increasingly being recognized. Early successes in identifying disease-associated CNVs via a candidate gene
approach mandate that future disease association studies need to include structural genetic variation. Such
analyses should not rely on previously developed methodologies that were designed to evaluate single
nucleotide polymorphisms (SNPs). Instead, development of novel technical, statistical, and epidemiologic
methods will be necessary to optimally capture this newly-appreciated form of genetic variation in a
meaningful manner.
© 2008 Elsevier Inc. All rights reserved.“When all you have is a hammer, everything begins looking
like nails.”
Abraham Maslow (1908–1970)
Among the many important insights derived from completion of
the Human Genome Project was the recognition of the abundance of
single nucleotide polymorphisms (SNPs) as a major source of genetic
variation, leading to speculation that the bulk of phenotypic variability
in humanpopulations is due to single base changes. As a result, intense
efforts were made to develop high-throughput sequencing and SNP
genotyping platforms, SNP databases, detailed linkage disequilibrium
maps (through the International HapMap Project), and statistical
methodologies for analyzing SNP genotype and haplotype data in
mapping disease-susceptibility genes. Until recently, the overwhel-
ming majority of gene-mapping studies have focused exclusively on
the role of SNPs in human diseases. Indeed, using population-based
studies to identify genetic determinants of common disease, dozens of
SNP-based susceptibility variants have been identiﬁed for human
diseases as diverse as diabetes [1,2],macular degeneration [3,4], cancer
[5,6], asthma [7] and Crohn disease [1,8]. However, studies over the
past three years have resulted in increasing recognition of the
critical role of structural genetic variation (most of which appear
to be in the form of copy-number variation) in modulating gene
expression and disease phenotype. In fact, copy-number variants
(CNVs) are now known to be a prevalent form of common geneticl rights reserved.variation and represent a substantial proportion of total genetic
variability in human populations. Moreover, a few association
studies have already demonstrated the importance of CNVs as
disease-susceptibility variants, with speciﬁc CNVs found to confer
differential risk to HIV infections [9], autoimmune disease [10–12],
and asthma [13–16] (Table 1). Recently, genome-wide surveys have
demonstrated that rare CNVs altering genes in neurodevelopmental
pathways are implicated in autism spectrum disorder [17] and
schizophrenia [18]. It is therefore becoming increasingly clear that
genetic studies of complex diseases must pay closer attention to
the contribution of CNVs.
In contrast to the well-developed resources available for SNP-
association studies, we are still in the early phases of incorporating
structural genetic variation in genome-wide association studies.
Nevertheless, we anticipate a burgeoning focus on structural genetic
variation in human disease over the next few years, and foresee the
development of many tools needed for such studies. In this
commentary, we provide a brief description of the presently known
landscape of structural genetic variation, review recent successes in
identifying CNVs associated with human diseases, and then address
the current challenges of CNV-association studies, including the
limitations of current genotyping platforms and available statistical
methods.
Presently known landscape of CNVs
Structural genetic variation refers to a class of genomic alterations
of DNA that usually span more than 1000 bases (reviewed in Freeman
Table 1
Replicated associations of DNA copy-number variants with common complex disease
Locus CNV frequency Clinical phenotype CNV type Risk estimate (odds ratio) Comments
CCL3L1 [9,11] 10–20% HIV/AIDS susceptibility [9] Deletion 0.67–0.90 CCL3L1 inhibits HIV cellular
entry [50]. Higher CCL3L1 number
increases CCL3L1 expression [49]
Rheumatoid arthritis [11] Gain: N2 copies 1.34
FCGR3B [10] Deletion: ∼25% Systemic autoimmune disease Deletion 1.58–2.56a CNV associated with
glomerulonephritis in rats and
humans [51]
Gain: ∼15%
C4 [12] ∼40% Systemic lupus erythematosus Deletion Absence: 5.27 N75% of C4 or C1 deletion carriers have
SLE-like disease [12]. Strongest SLE
genetic risk factor thus far in
blacks [52]
Carrier: 1.61
Gains: 0.57
DEFB4 [33,34] 2–12 copies (median 4) Colonic Crohn disease [33] Loss: b4 copies 3.06 ↓ number associated with ↓ mucosal
gene expression. [33]Psoriasis [34] Gain: N5 copies 1.69
GSTM1 [13–16] Up to 50% Asthma, lung function, allergic response Deletion 1.59–1.89 Potent antioxidant. Deletion related to
many adverse asthma-related
outcomes (see text).
a FCGR3B demonstrates phenotypic pleiotropy: OR for lupus 2.21; for Wegener's granulomatosis 1.58–2.46; for microscopic polyangiitis 2.56.
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changes such as copy-number variants (CNVs), and less common
balanced variations involving chromosomal inversions, insertions,
and translocations. Here, we focus on CNVs, themost prevalent type of
structural genetic variation.
Structural genetic variation has long been known to impact
health, though until very recently this impact was thought to be
limited to rare genomic disorders. A handful of Mendelian disorders,
such as Williams–Beuren Syndrome (deletion at chromosome region
7q11.23) or Charcot–Marie Tooth neuropathy Type 1A (duplications
of peripheral myelin protein-22 at chromosome region 17p11.2), are
caused exclusively by recurrent DNA copy-number changes at criti-
cal loci. However, with the realization of the existence of widespread
common structural variation among otherwise healthy indivi-
duals [21–23], greater attention is now being focused on whether
this type of genetic variation inﬂuences more common human
diseases.
The current map of structural variation in the human genome is far
from complete [24]. While several databases exist to catalog this
newly-appreciated form of human genetic variation (notably the
Database of Genomic Variants — http://projects.tcag.ca/variation/ and
the Human Structural Variation Database — http://humanparalogy.gs.
washington.edu/structuralvariation/), quality control is lacking, and
studies have differed in technological approaches, precise boundary
deﬁnition of CNVs, DNA quality, and even discrepancies in terminol-
ogy [24]. Nevertheless, the latest compilation of data on structural
genetic variation (The Database of Genomic Variants — November 29,
2007) from 46 different articles over the past three years indicates that
as many as 4878 loci (comprised of 11,784 different CNV entries) have
now been identiﬁed. We anticipate that our understanding of the
location and extent of CNV in the human genome will improve
markedly in the next few years. Emerging technologies are more
sensitive for detection of CNVs and provide more precise deﬁnition of
boundaries (e.g. Perry et al. [25]). Undoubtedly, as a clearer map of
human structural genetic variation emerges, we will begin to more
comprehensively include this type of genetic variation in genome-
wide association studies that attempt to elucidate the role of CNVs in
human disease.
CNVs in health and disease
Several distinguishing features of CNVs support their role in
disease pathogenesis. First, though less abundant than SNPs, it has
been suggested that CNVs account for more nucleotide variation than
do SNPs, on account of their sheer size [23]. By spanning thousands of
bases, CNVs often encompass (and can sometimes disrupt) functionalDNA sequences. Second, there appears to be an enrichment of cur-
rently known CNVs toward “environmental sensor” genes — i.e. genes
that are not necessarily critical for early embryonic development, but
rather help us to perceive and interact successfully with our ever-
changing environment [22,23]. This includes enrichment for olfactory
receptors, immune and inﬂammatory response genes, cell signaling
and cell adhesion molecules, structural proteins, and ion channels.
Third, like other forms of genetic variation, both purifying and
adaptive natural selective pressures appear to have inﬂuenced the
frequency distribution of selective CNVs, suggesting their functional
signiﬁcance [26–29]. Lastly, a recent comparison of the relative impact
of SNPs and CNVs on gene expression noted that a substantial
proportion (∼18%) of gene expression variability was attributable to
known CNVs greater than ∼40 kb in size [30]. Notably, 53% of genes
whose expressionwas inﬂuenced by CNVs had the corresponding CNV
outside of the actual gene, suggesting that many CNVs could affect
important regulatory sequences that are situated at a distance from
the actual target gene.
Given these features, it is perhaps not surprising that early
genetic association studies of known CNVs have quickly produced
promising results. Presented in Table 1 are recent examples of copy-
number variable loci implicated in the pathogenesis of complex
traits, where the association has been observed in at least two
independent populations. These loci share several noteworthy
features that may provide important insights into the role CNVs
may play in complex diseases. First, the copy-number frequencies for
all ﬁve loci are high – greater than 10% in all cases – conﬁrming that
the allelic spectrum of disease-related CNVs is not restricted to rare
variants. Second, with the exception of the CCL3L1 HIV/AIDS
protective alleles, the genetic risk conferred by these variants is
quite high (relative to SNPs, particularly in the context of polygenic,
complex traits). Currently available data suggest that many CNVs
confer greater disease risk than SNPs and in some cases these CNV-
based disease-susceptibility variants appear to increase risk by as
much as 30%. Although we caution over interpretation of these early
estimates (given that risk tends to be overestimated in initial
studies due to the so-called “winner's curse” [31,32]), these early
returns do support an important role for CNVs in the genetic etiology
of common diseases.
These early studies also suggest that copy-number variable loci
may exhibit copy-number dependent genetic pleiotropy. We note that
for two of the loci listed in Table 1, gains and losses are associated with
distinct phenotypes (HIV and Rheumatoid Arthritis for CCL3L1; Crohn
disease and Psoriasis for DEFB4) ([9,11,33,34]). These observations are
reminiscent of neuropathies associated with copy-number variation
at the Peripheral Myelin Protein 22 (PMP22) locus, where PMP22
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1677316) and PMP22 deletions cause hereditary neuropathy with
liability to pressure palsies (also known as bulb diggers' palsy)
(PubMedID: 8422677). Whether this phenomenonwill be observed at
other copy-variable loci is unclear.
Another striking feature shared by the loci listed in Table 1 is that
all are immune or inﬂammatory-related genes. Though certainly a
function of the diseases studied in these surveys, this enrichment is
consistent with the distribution of functional gene classes in CNV
regions, where inﬂammatory and immune-related genes were among
the most overrepresented [35].
It is important to recognize that all of these loci were identiﬁed
using candidate gene approaches rather than hypothesis-free, ge-
nome-wide surveys. It is therefore unclear whether the above
observations (relating to allele frequency distribution, effect sizes
and functional class representation) will continue to hold as novel loci
are identiﬁed throughgenome-wide association studiesnot predicated
on prior biological knowledge. In one recent genome-wide CNV-
association study on autism spectrum disorder (ASD) [17], 264 families
(including 165 families with autistic children and 99 control families)
were screened for de novo CNV mutations. In this study, the authors
observed a disproportionate incidence of de novomutations in families
with ASD (12 deletions and 2 duplications among affected families
compared to 2 gains among controls). This represented an approximate
3-fold increase in de novo mutation rate. All of the ASD-associated
CNVsharbored at least one gene, several ofwhichhave been implicated
in clinical contexts to overlapwith autism. A similar study [18] showed
the importance of rare CNVs at multiple sites in schizophrenia. In this
study, the authors observed that novel (that is, not present in the
Database of Genomic Variants) microdeletions and microduplications
(N100 kilobases) were present in 15% of schizophrenia cases, a
frequency three times that in controls. Notably, mutations in cases
disproportionately affected genes from signaling networks controlling
neurodevelopment, including neuregulin and glutamate pathways.
The early successes described above suggest that there will be a
sharp increase in the number of published CNV-association studiesFig. 1. Raw copy-number measurements vs. CNV calls for a CNV showing a continuous dis
distributed, simulated phenotype and the intensity measurements at a single SNP position
approximately 1200 individuals (CAMP study [53]). On the right side, the association between
using a local false discovery rate (locFDR) approach [54], applied to the intensity measurem
classifying the rawmeasurements into discrete calls may result in loss of power compared to
correlation coefﬁcient).over the coming years. In anticipation of this, we stress that there still
remain considerable technical, methodological, and analytical chal-
lenges related to CNV-based association studies that must be
recognized and carefully addressed.
Technical challenges in CNV studies
CNV-based association studies pose additional unique challenges,
including choice of genotyping platform (for a recent review, please
see Carter [36]) and DNA quality control. Three broad platform classes
are currently available for genome-wide copy-number surveys: (1)
Large insert clone-based comparative genomic hybridization (CGH),
where differentially-labeled test and reference samples compete for
binding to DNA from large insert genomic clones — such as BACs (e.g.,
Fiegler et al. [37]); (2) long, isothermic oligonucleotide-based CGH
arrays [38] (where differentially-labeled test and reference samples
compete for binding to 50–65mer oligonucleotides that are designed
to have similar thermodynamic kinetics); and (3) SNP-based arrays
[39] (one-sample arrays where intensity values derived from
genotyping assays are used to infer copy number). Large insert
clone-based CGH arrays have the highest signal-to-noise ratios, but
are limited in their use to association studies due to their relatively
low effective resolution (max. 15–35 kb). Conversely, SNP-based
methods are optimized for high-throughput studies, and the high SNP
density on most current arrays provide high resolution (∼3 kb) in
regions of the genome that are well represented. Furthermore,
genome-wide SNP data are already being generated from genome-
wide association studies (GWAS) across a variety of complex diseases,
and thus it would be attractive to simply reanalyze these existing data
for preliminary genome-wide CNV surveys. However, unfortunately,
SNP-based arrays have the poorest signal-to-noise ratios (an order of
magnitude worse than CGH), and it remains unclear whether the
convenience of data availability will offset the high measurement
error currently observed. Long oligonucleotide arrays offer both
intermediate resolution and performance, and can be useful for
high-resolution CNV detection, validation and characterization. Onetribution. Shown in this ﬁgure, on the left side, is the association between a normally
within a known copy-number variable region on chromosome 21 using a dataset of
the same phenotype and the CNV calls (loss/no change) is shown. Losses were detected
ents. As can be observed, for CNVs showing a continuous intensity distribution, forcibly
the original measurements, as illustrated by the drop in the R^2 value (the square of the
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autism screen described by both Sebat et al. [17], andWalsh et al. [18].
Newer platforms have now been developed that strategically include
many probes (that aim to collectively detect CNVs, rather than SNPs)
in a manner as to allow a single assay to effectively capture both SNP
and CNV data (e.g., the Affymetrix Human SNP 6.0 array and Illumina 1
million feature genotyping assay). Association studies using these
platforms are ongoing and therefore preclude comment on their
performance at this time.
All of the currently available platforms rely on efﬁcient DNA
hybridization, which can be signiﬁcantly impaired by poor quality
sample DNA. DNA sample quality is of particular concern in case–
control studies where genomic DNA being used is collected from
different sites and over long periods of time. As quantitative measures
are sensitive to DNA degradation or contamination, spurious evidence
of association may arise if sample ascertainment and DNA storage
techniques differ between case and control samples. Similar bias can
potentially be introduced in family-based studies if samples from
probands and parents are collected under different conditions. Where
possible, DNA samples from all sites should be handled uniformly, and
an assessment of the DNA quality (including OD measurements),
estimates of sample purity, DNA degradation and DNA concentration
should be performed prior to genotyping.
Statistical challenges in analysis of CNV associations with
human disease
Genetic epidemiology of CNVs is still in its infancy— so too are the
statistical methods for the analysis of CNV associationwith disease. As
discussed above, genotyping platforms vary in their signal-to-noise
ratio and also in their ability to deﬁne precise CNV genotypes (i.e.
discrete copy number). Current CNV typing technologies produce
quantitative measures meant to reﬂect total DNA amount in a given
sample. In contrast to SNP genotyping, oftentimes the distribution of
these measurements is continuous, making it difﬁcult to accurately
estimate DNA copy number. Currently only a small fraction of the
known CNVs are genotypable.
Two main statistical methodologies can be employed for CNV
analyses, and they differ in their need for precise CNV quantiﬁcation.
The ﬁrst involves a two-step procedure, based on ﬁrst inferring the
underlying genotype and then performing a regular test of association
[40,41]. Because it depends on “genotypable” markers, this class of
statistical methodologies is currently only applicable to a limited
number of CNVs. Also, it is not immediately clear how the uncertainty
of CNV genotype calling should be incorporated in the analysis; when
raw measurements show a continuous distribution, forcibly classi-
fying them into discrete copy-number classes (e.g. gain, no change, or
loss) may result in the loss of substantial information and statistical
power relative to the raw measurements [42] (see also Fig. 1). The
second methodology bypasses the genotype calling step and instead,
directly analyzes the intensity measurements which are thought to
reﬂect the true underlying copy number. This strategy has been
advocated in several recent papers [30,42].
For case–control designs, classical statistical methods (e.g. para-
metric (t-tests), non-parametric (Mann–Whitney U test) etc.) can be
employed. Also, some of the methods that are already available for
SNP genotype data can potentially be adapted to the analysis of
signal intensity data (e.g. population stratiﬁcation methods such as
Eigenstrat, [43]). For family-based study designs, a method extending
family-based tests (FBATs) [44,45] to deal with copy-number variation
has recently been proposed [46]. Like the FBAT method for SNP data,
CNV-FBAT is based on the covariance between offspring trait and
offspring CNV data (adjusted for the parental CNV data), where the
CNV data here are represented by the normalized signal intensity
measurements. The robustness properties of the genotype FBAT
approach are maintained and previously developed FBAT extensions(including FBATs for time-to-onset, multivariate FBATs, and FBAT-
testing strategies) can be directly transferred to the analysis of CNVs
[44]. This methodology has the advantage of using as much data as
possible, without affecting power in a signiﬁcant way. However, while
signal intensity-based CNV data provide valuable information and can
be used directly to perform association tests, knowing the true
underlying genotype is important for validating the association signal
and providing further insight into the biologicalmechanisms bywhich
a CNV inﬂuences disease.
Failure to correct for biases in data collection or processing prior to
performing the association test may result in spurious associations
with either of the statistical approaches. Therefore, it is mandatory
that disease associations be veriﬁed using alternate technologies and/
or independent datasets. This potential problem may be accentuated
with the case–control design, which depends on selection of a suitable
control sample. As discussed above, the control sample needs to come
from a comparable population, with nearly identical DNA quality,
preparation, and handling among samples in the case and control
populations. Family-based designs can alleviate some of these
problems, as the parents and other family members of the proband
act as well-matched controls. However, care needs to be taken that
samples from family members are collected and evaluated under
similar conditions as the proband. A further advantage of family-based
study designs is their potential for discriminating between de novo
and inherited CNVs, once an association between a CNV and a pheno-
type has been established.
Epidemiologic challenges in the design of CNV-based
association studies
The novelty of studying CNV should not obscure the need for
meticulous attention to epidemiologic study design. CNV-association
studies should employ the same rigorous standards that have been
used in conventional SNP-based genetic epidemiology studies. These
include assurance of adequate sample size to detect modest genetic
effects, appropriate adjustment of signiﬁcance thresholds to adjust for
multiple comparison testing, provision of evidence for reproducible
association in independent populations, and rigorous assessment and
adjustment for population stratiﬁcation. This latter point warrants
elaboration. Like SNPs, most common CNVs are shared between
populations and follow frequency distributions reminiscent of other
forms of genetic variation [28]. However, like SNPs, some CNVs
demonstrate notable between-population differences in allele fre-
quency distribution (representing ∼11% of the variance in between-
population differences) [28]. As a consequence, CNV-association
studies, like SNP-association studies, are susceptible to bias from
population stratiﬁcation, whereby spurious genetic association could
be observed between marker and trait simply due to differing
ancestral composition (and hence genotype frequency distribution)
between cases and controls [28,47]. There are several methods for
addressing population stratiﬁcation, including stringent sampling of
cases and controls from homogenous ancestral groups, use of family-
based designs, and analytic methods (including sequential screening
for and quantifying population stratiﬁcation using random sets of
markers with subsequent adjustment of association test statistics by
the degree of observed stratiﬁcation [48]).
Conclusions
The study of structural genetic variation in human diseases is a
new and rapidly evolving ﬁeld. The main limitations of this ﬁeld of
study relate to the lack of technological and statistical tools dedicated
to these efforts, and reliance on the “hammers” developed for the
study of SNPs. Over the next few years, a much more thorough
understanding of the extent and precise location of copy-number
variationwill likely be available as new platforms become available to
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comprehensively understand the role of these genetic variants in the
pathogenesis of human diseases. However, in addition to the
development of better CNV genotyping platforms, we stress that
rigorous attention to study design and statistical analysis is critical so
as not to relive past experiences of early disease association studies
that yielded “unreplicable” and all too often false-positive results.
Whenever possible, initial reports of CNV-disease association should
include independent evidence of replication in other studies and
populations. Generating such data will frequently require collabora-
tion between research groups, and may include sharing of DNA
samples given the current technical challenges of CNV genotyping and
operator-dependence of quantitative genotyping assays like qPCR.
Despite the many obstacles yet to be overcome, we foresee CNVs
quickly taking their place alongside SNPs in genetic epidemiology
studies. Once identiﬁed, these loci can then be evaluated experimen-
tally using animal models that recapitulate the disease-associated
molecular defect (e.g., knock-out mice for CNV losses and over-
expressing transgenic models for CNV gains) and the development of
speciﬁc molecular therapeutics, ultimately leading to novel therapies
for our most common diseases.
References
[1] Wellcome Trust Case Control Consortium, Genome-wide association study of
14,000 cases of seven common diseases and 3,000 shared controls, Nature 447
(2007) 661–678.
[2] R. Saxena, et al., Genome-wide association analysis identiﬁes loci for type 2
diabetes and triglyceride levels, Science 316 (2007) 1331–1336.
[3] A.O. Edwards, et al., Complement factor H polymorphism and age-relatedmacular
degeneration, Science 308 (2005) 421–424.
[4] R.J. Klein, et al., Complement factor H polymorphism in age-related macular
degeneration, Science 308 (2005) 385–389.
[5] D.F. Easton, et al., Genome-wide association study identiﬁes novel breast cancer
susceptibility loci, Nature 447 (2007) 1087–1093.
[6] D.J. Hunter, et al., A genome-wide association study identiﬁes alleles in FGFR2
associated with risk of sporadic postmenopausal breast cancer, Nat. Genet. 39
(2007) 870–874.
[7] M.F. Moffatt, et al., Genetic variants regulating ORMDL3 expression contribute to
the risk of childhood asthma, Nature 448 (2007) 470–473.
[8] R.H. Duerr, et al., A genome-wide association study identiﬁes IL23R as an
inﬂammatory bowel disease gene, Science 314 (2006) 1461–1463.
[9] E. Gonzalez, et al., The inﬂuence of CCL3L1 gene-containing segmental duplica-
tions on HIV-1/AIDS susceptibility, Science 307 (2005) 1434–1440.
[10] M. Fanciulli, et al., FCGR3B copy number variation is associated with susceptibility
to systemic, but not organ-speciﬁc, autoimmunity, Nat. Genet. 39 (2007) 721–723.
[11] C. McKinney, et al., Evidence for an inﬂuence of chemokine ligand 3-like 1
(CCL3L1) gene copy number on susceptibility to rheumatoid arthritis, Ann.
Rheum. Dis. (2007).
[12] Y. Yang, et al., Gene copy-number variation and associated polymorphisms of
complement component C4 inhumansystemic lupus erythematosus (SLE): lowcopy
number is a risk factor for and high copy number is a protective factor against SLE
susceptibility in European Americans, Am. J. Hum. Genet. 80 (2007) 1037–1054.
[13] C. Brasch-Andersen, et al., Possible gene dosage effect of glutathione-S-
transferases on atopic asthma: using real-time PCR for quantiﬁcation of GSTM1
and GSTT1 gene copy numbers, Hum. Mutat. 24 (2004) 208–214.
[14] T.E. Ivaschenko, O.G. Sideleva, V.S. Baranov, Glutathione-S-transferase micro and
theta gene polymorphisms as new risk factors of atopic bronchial asthma, J. Mol.
Med. 80 (2002) 39–43.
[15] C.N. Palmer, et al., Glutathione S-transferase M1 and P1 genotype, passive
smoking, and peak expiratory ﬂow in asthma, Pediatrics 118 (2006) 710–716.
[16] P. Piirila, et al., Glutathione S-transferase genotypes and allergic responses to
diisocyanate exposure, Pharmacogenetics 11 (2001) 437–445.
[17] J. Sebat, et al., Strong association of de novo copy number mutations with autism,
Science 316 (2007) 445–449.
[18] T. Walsh, et al., Rare structural variants disrupt multiple genes in neurodevelop-
mental pathways in schizophrenia, Science 320 (2008) 539–543.
[19] J.L. Freeman, et al., Copy number variation: new insights in genome diversity,
Genome Res. 16 (2006) 949–961.
[20] L. Feuk, A.R. Carson, S.W. Scherer, Structural variation in the human genome, Nat.
Rev. Genet. 7 (2006) 85–97.[21] A.J. Iafrate, et al., Detection of large-scale variation in the human genome, Nat.
Genet. 36 (2004) 949–951.
[22] J. Sebat, et al., Large-scale copy number polymorphism in the human genome,
Science 305 (2004) 525–528.
[23] E. Tuzun, et al., Fine-scale structural variation of the human genome, Nat. Genet.
37 (2005) 727–732.
[24] S.W. Scherer, et al., Challenges and standards in integrating surveys of structural
variation, Nat. Genet. 39 (2007) S7–15.
[25] G.H. Perry, et al., The ﬁne-scale and complex architecture of human copy-number
variation, Am. J. Hum. Genet. 82 (2008) 685–695.
[26] D.Q. Nguyen, C. Webber, C.P. Ponting, Bias of selection on human copy-number
variants, PLoS Genet. 2 (2006) e20.
[27] G.H. Perry, et al., Diet and the evolution of human amylase gene copy number
variation, Nat. Genet. (2007).
[28] R. Redon, et al., Global variation in copy number in the human genome, Nature
444 (2006) 444–454.
[29] H. Stefansson, et al., A common inversion under selection in Europeans, Nat.
Genet. 37 (2005) 129–137.
[30] B.E. Stranger, et al., Relative impact of nucleotide and copy number variation on
gene expression phenotypes, Science 315 (2007) 848–853.
[31] J.P. Ioannidis, E.E. Ntzani, T.A. Trikalinos, D.G. Contopoulos-Ioannidis, Replication
validity of genetic association studies, Nat. Genet. 29 (2001) 306–309.
[32] K.E. Lohmueller, C.L. Pearce, M. Pike, E.S. Lander, J.N. Hirschhorn, Meta-analysis of
genetic association studies supports a contribution of common variants to
susceptibility to common disease, Nat. Genet. 33 (2003) 177–182.
[33] K. Fellermann, et al., A chromosome 8 gene-cluster polymorphism with low
human beta-defensin 2 gene copy number predisposes to Crohn disease of the
colon, Am. J. Hum. Genet. 79 (2006) 439–448.
[34] E.J. Hollox, et al., Psoriasis is associated with increased beta-defensin genomic
copy number, Nat. Genet. 40 (2008) 23–25.
[35] G.M. Cooper, D.A. Nickerson, E.E. Eichler, Mutational and selective effects on copy-
number variants in the human genome, Nat. Genet. 39 (2007) S22–29.
[36] N.P. Carter, Methods and strategies for analyzing copy number variation using
DNA microarrays, Nat. Genet. 39 (2007) S16–S21.
[37] H. Fiegler, et al., Accurate and reliable high-throughput detection of copy number
variation in the human genome, Genome Res. 16 (2006) 1566–1574.
[38] B. Carvalho, E. Ouwerkerk, G.A. Meijer, B. Ylstra, High resolution microarray
comparative genomic hybridisation analysis using spotted oligonucleotides,
J. Clin. Pathol. 57 (2004) 644–646.
[39] D. Komura, et al., Genome-wide detection of human copy number variations using
high-density DNA oligonucleotide arrays, Genome Res. 16 (2006) 1575–1584.
[40] J.R. Kohler, D.J. Cutler, Simultaneous discovery and testing of deletions for
disease association in SNP genotyping studies, Am. J. Hum. Genet. 81 (2007)
684–699.
[41] K. Kosta, et al., A Bayesian approach to copy-number-polymorphism analysis in
nuclear pedigrees, Am. J. Hum. Genet. 81 (2007) 808–812.
[42] S.A. McCarroll, D.M. Altshuler, Copy-number variation and association studies of
human disease, Nat. Genet. 39 (2007) S37–42.
[43] A.L. Price, et al., Principal components analysis corrects for stratiﬁcation in
genome-wide association studies, Nat. Genet. 38 (2006) 904–909.
[44] C. Lange, N.M. Laird, On a general class of conditional tests for family-based
association studies in genetics: the asymptotic distribution, the conditional
power, and optimality considerations, Genet. Epidemiol. 23 (2002) 165–180.
[45] C. Lange, et al., A new powerful non-parametric two-stage approach for testing
multiple phenotypes in family-based association studies, Am. J. Hum. Genet. 73
(2003) 613 (abstract).
[46] I. Ionita-Laza, et al., Lange, On the analysis of copy-number variations in genome-
wide association studies: a translation of the family-based association test, Genet.
Epidemiol. 32 (2008) 273–284.
[47] D.F. Conrad, M.E. Hurles, The population genetics of structural variation, Nat.
Genet. 39 (2007) S30–S36.
[48] J. Marchini, L.R. Cardon, M.S. Phillips, P. Donnelly, The effects of human population
structure on large genetic association studies, Nat. Genet. 36 (2004) 512–517.
[49] J.R. Townson, L.F. Barcellos, R.J. Nibbs, Gene copy number regulates the production
of the human chemokine CCL3-L1, Eur. J. Immunol. 32 (2002) 3016–3026.
[50] R.J. Nibbs, J. Yang, N.R. Landau, J.H. Mao, G.J. Graham, LD78beta, a non-
allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor
interactions and potent HIV suppressive activity, J. Biol. Chem. 274 (1999)
17478–17483.
[51] T.J. Aitman, et al., Copy number polymorphism in Fcgr3 predisposes to
glomerulonephritis in rats and humans, Nature 439 (2006) 851–855.
[52] M.L. Olsen, et al., C4A gene deletion and HLA associations in black Americans with
systemic lupus erythematosus, Immunogenetics 30 (1989) 27–33.
[53] Childhood Asthma Management Program Research Group, The Childhood
Asthma Management Program (CAMP): design, rationale, and methods, Control
Clin. Trials 20 (1999) 91–120.
[54] B. Efron, Large-scale simultaneous hypothesis testing: the choice of a null
hypothesis, J. Am. Stat. Assoc. 99 (2004) 96–104.
